ERBB2 and cancer: RTK inhibitors, and tyrosine kinase inhibitors, in general, show the highest relative risk (RR = 5.6) of high-grade cardiac toxicity among anti-cancer drugs.722 Selective RTK inhibitors that play a major role in development of cardiac manifestations target HER2 and VEGFR.723 In contrast with anthracyclines, tyrosine kinase inhibitors were thought to induce cumulative dose-independent, late-onset, non-progressive and partially reversible cardiac toxicities.